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SUMMARY
Introduction Hydroxycarbamide, used in therapy of hemoglobinopathies, enhances nitric oxide (NO) 
production both in primary human umbilical vein endothelial cells (HUVECs) and human bone marrow 
endothelial cell line (TrHBMEC). Moreover, NO increases γ-globin and fetal hemoglobin levels in human 
erythroid progenitors.
Objective In order to find out whether simple physiologic stimulation of NO production by components 
of hematopoietic microenvironment can increase γ-globin gene expression, the effects of NO-inducer 
bradykinin were examined in endothelial cells.
Methods The study was performed in co-cultures of human erythroid progenitors, TrHBMEC and HUVECs 
by ozone-based chemiluminescent determination of NO and real-time quantitative RT-PCR.
Results In accordance with previous reports, the endogenous factor bradykinin increased endothelial cell 
production of NO in a dose- and time-dependent manner (0.1-0.6 μM up to 30 minutes). This induction of 
NO in HUVECs and TrHBMEC by bradykinin was blocked by competitive inhibitors of NO synthase (NOS), 
demonstrating NOS-dependence. It has been shown that bradykinin significantly reduced endothelial 
NOS (eNOS) mRNA level and eNOS/ß-actin ratio in HUVEC (by twofold). In addition, bradykinin failed 
to increase γ-globin mRNA expression in erythroid progenitors only, as well as in co-culture studies of 
erythroid progenitors with TrHBMEC and HUVEC after 24 hours of treatment. Furthermore, bradykinin 
did not induce γ/β globin ratio in erythroid progenitors in co-cultures with HUVEC.
Conclusion Bradykinin mediated eNOS activation leads to short time and low NO production in endothe-
lial cells, insufficient to induce γ-globin gene expression. These results emphasized the significance of 
elevated and extended NO production in augmentation of γ-globin gene expression.
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INTRODUCTION
Nitric oxide (NO) is an important intracellular 
and intercellular signaling molecule with a sig-
nificant role in maintaining normal blood pres-
sure in vivo. The production of NO in the body, 
from the non-aromatic amino acid L-arginine 
and molecular oxygen, is catalyzed by a family 
of enzymes called NO synthases (NOSs). One 
of them is endothelial NOS (eNOS), expressed 
in endothelial cells, cardiac myocytes and blood 
platelets. eNOS activity is controlled at the tran-
scriptional and post-transcriptional levels as 
well as at the post-translational level [1]. One 
of the agonists that contribute to activation of 
eNOS in endothelial cells is bradykinin, a po-
tent inducer of eNOS activity [2]. Bradykinin is 
an endogenous non-peptide derived from pro-
teolysis of higher molecular weight precursor 
proteins synthesized in the liver and hypothala-
mus. Bradykinin acts as a local hormone whose 
pharmacological actions include hypertension, 
increase in vascular permeability and blood 
coagulation [3]. In addition, it is another key 
determinant of vascular function since its B2 
receptors in endothelial cells modulate vasodi-
lation, vascular permeability, mitogenesis and 
adhesion molecule expression [4].
Hydroxycarbamide has demonstrated ef-
ficacy in adults with sickle cell disease. Hy-
droxycarbamide treatment is associated with 
fewer vaso-occlusive pain episodes and hospi-
talizations, and lower total costs of care. The 
incidence of painful crises has been reduced 
significantly, as well as the rates of the acute 
chest syndrome and blood transfusion [5]. 
Long-term follow-up showed 40% reduction 
in mortality among those who received hy-
droxycarbamide [6]. In sickle cell disease, the 
protective effect of fetal hemoglobin (HbF) is 
mediated primarily by decreasing intravascular 
sickling, resulting in the increased NO bioavail-
ability [7]. Moreover, adult hemoglobin (HbA) 
is expressed in human arterial endothelial cells 
and augmented at the myoendothelial junction, 
where regulates the NO effects on vascular re-
activity. The endothelial HbA hem iron in the 
ferric Fe3+ status allows NO signaling, and this 
signaling is not active when HbA is reduced 
to the ferrous Fe2+ condition [8]. According to 
our previous results, HbF inducer hydroxycar-
bamide increased NO production in both pri-  
190
  
doi: 10.2298/SARH1404189C
Čokić V. P. et al. Bradykinin Stimulation of Nitric Oxide Production is not Sufficient for Gamma-Globin Induction
mary human umbilical endothelial cells (HUVECs) and 
human endothelial cell line (TrHBMEC) through eNOS 
phosphorylation [9]. Moreover, during human erythroid 
differentiation in vitro, eNOS mRNA and protein levels 
were initially high but then declined steadily, as did the 
production of NO derivatives [10]. In addition, NO in-
creased γ-globin levels, the γ/ß-globin ratio and HbF levels 
in human erythroid cells [11].
OBJECTIVE
The erythroid progenitors in co-cultures with hematopoi-
etic stromal cells, either macrophages or endothelial cells 
stimulated by NO-inducer hydroxycarbamide, demon-
strated increased γ-globin gene expression in comparison 
to the erythroid cells only [12]. Therefore, NO mediated 
stimulation may have resources in the microenvironment 
supported by delivered endogenous factors, besides exog-
enous treatment. To explore possibility whether physio-
logic stimulation of constitutive NO production by hemat-
opoietic microenvironment can influence γ-globin gene 
expression, the effects of bradykinin were investigated in 
co-cultures of human endothelial and erythroid progeni-
tor cells.
METHODS
Endothelial cell cultures
HUVECs (BioWhittaker Inc., Walkersville, MD, USA) 
were cultured in endothelial cell growth medium (ЕGM, 
BioWhittaker Inc.) at 37°C in a humidified environment 
containing 5% CO2. The cells from the 3rd and 4th pas-
sages were used in the present experiments. TrHBMECs 
were continuous bone marrow endothelial cell line from 
an adult female donor cells immortalized with the T an-
tigen of simian virus 40 [9]. TrHBMECs were cultured in 
culture flasks and dishes on 0.2% gelatin (Sigma-Aldrich, 
St Louis, MO, USA) at 37°C in Dulbecco’s modified es-
sential medium-low glucose (DMEM, Life Technologies, 
Carlsbad, CA, USA), supplemented with 10% fetal bovine 
serum (FBS, Gemini BioProducts, Woodland, CA), 100U/
ml penicillin, 100µg/ml streptomycin, 1 µg/ml folic acid 
(Sigma-Aldrich), and 3mM glutamine (Biofluids, Gaith-
ersburg, MD, USA). Experiments were done between 
passages 19 and 23. The EGM medium for HUVEC and 
DMEM medium for TrHBMEC already contained 0.36 
and 0.48 mM l-arginine, respectively. HUVECs and TrH-
BMECs were treated with bradykinin (Enzo Life Sciences 
Inc., Farmingdale, NY, USA) at concentrations indicated 
in Graphs, and at different time points, confluence was 
determined by inverted microscope. Additives were left 
throughout the periods of the culture. The viable cell 
counts were performed with the use of the Trypan-blue 
exclusion technique (BioWhittaker Inc.). 
Co-culture studies
A two-phase liquid culture protocol for erythroid cells was 
performed as previously described [11]. Briefly, peripheral 
blood-derived CD34+ cells were harvested and purified 
by negative selection using the StemSep Cell Separation 
method (Stem Cell Technologies Inc, Vancouver, Canada). 
The CD34+ cells were resuspended in the phase II medium 
which contained 30% FBS, 2 mmol/l glutamine, 100 U/ml 
penicillin, 100 μg/ml streptomycin, 1% deionized BSA, 10 
μmol/l β-mercaptoethanol, 1 μmol/l dexamethasone, 33 
μg/ml holo-transferrin, 10 ng/ml stem cell factor (SCF), 1 
ng/ml IL-3, 1 ng/ml GM-CSF (Sigma-Aldrich), and 1 U/ml 
human recombinant erythropoietin (Amgen Inc., Thou-
sand Oaks, CA, USA) to stimulate erythroid differentia-
tion. The adherent endothelial cell cultures were prepared 
in 6-well plates. Co-cultures of erythroid progenitor cells 
with TrHBMEC and HUVEC were treated with bradykinin 
(Enzo Life Sciences Inc.). The inserts containing erythroid 
progenitors were placed in the wells containing endothe-
lial cells, but separated from them by 1µm-pore semiper-
meable membrane (Biocoat BD Biosciences Discovery 
Labware, Bedford, MA, USA), while sharing the same 
phase II medium. Erythroid progenitor cells were placed 
in co-cultures on day 4, after initiation of phase II culture, 
and incubated for 24 hours in phase II medium at 37°C 
in the humidified atmosphere with 5% CO2 during treat-
ment by bradykinin. After incubation with bradykinin, the 
supernatants were transferred to black microplates and the 
fluorescence of extracellular NO/DAF-2 interaction was 
measured with a fluorescence microplate reader calibrated 
for excitation at 470 nm and emission at 550 nm. The in-
tracellular NO levels were measured by the cell permeable 
probe 4,5-diaminofluorescein diacetate (DAF-2DA, Enzo 
Life Sciences Inc.) using a microplate reader and Epics Elite 
flow cytometer (Coulter, Hialeah, FL, USA).
Ozone-based chemiluminescent determination of 
nitrite
For nitrite measurements, confluent HUVECs in 6-well 
plates were washed once with HEPES (N-2-hydroxyethyl-
piperazine-N’-2-ethanesulfonic acid) buffer (BioWhittaker 
Inc.) and endothelial basal medium (EBM) was added. Af-
ter 3 hours, the medium was replaced with a new EBM 
and cells were treated with bradykinin. Confluent TrH-
BMECs in 6-well plates were washed once, and the me-
dium was replaced with DMEM supplemented with 100U/
ml penicillin, 100µg/ml streptomycin, 1µg/ml folic acid 
and 3mM glutamine. The cells were left overnight at 37°C 
(glutamine was removed for eNOS inhibitor experiments). 
The following day, the medium was replaced with DMEM 
supplemented with 100U/ml penicillin, 100µg/ml strep-
tomycin and 1µg/ml folic acid. For the eNOS inhibitors, 
TrHBMECs and HUVECs were pretreated for 30 minutes 
with NG-Nitro-L-arginine-methyl ester (L-NAME) and 
NG-Nitro-l-arginine (Enzo Life Sciences Inc.), respective-
ly, and then exposed to bradykinin. The supernatant of      
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treated cells was immediately frozen on dry ice and stored 
at -80°C. Frozen samples were thawed and then the level 
of nitrite was determined with the Sievers Model 280 NO 
analyzer (Sievers, Boulder, CO, USA). NO was measured 
by nitrite reduction in acidified KI containing 7 ml of gla-
cial acetic acid, 2ml of distilled water, 50 mg of KI and a 
crystal of iodine that was added to yield a concentration 
of 6-20 mmol/l (Sigma-Aldrich). Helium was bubbled 
through the reaction mixture.
RNA extraction and real-time quantitative reverse 
transcriptase PCR
For isolation of total RNA from erythroid cells, the RNeasy 
procedure was used (Qiagen, Valencia, CA, USA) accord-
ing to the manufacturer’s instructions. The concentration 
and integrity of total RNA were assessed using an 8453 UV/
Visible Spectrophotometer (Hewlett-Packard GmbH, Wald-
bronn, Germany) and Agilent 2100 Bioanalyzer Software 
(Agilent Technologies, Waldbronn, Germany). One micro-
gram of total RNA was reverse transcribed with SuperScript 
II RNase H- Reverse Transcriptase kit (Life Technologies). 
The specific primers of human γ- and β-globin, eNOS genes 
as well as TAQMAN probes were designed using Primer 
Express software and prepared on the ABI 394 synthesizer 
as previously described [11, 13]. Platinum Quantitative 
PCR SuperMix-UDG (Life Technologies) was used, con-
taining final concentration of 200 µM 2’-deoxynucleoside 
5’-triphosphates (dNTPs), 0.5 µM Rox reference dye (Life 
Technologies), 0.2 µM each of TAQMAN probe, sense and 
antisense primers. Expression levels were determined using 
the associated SDS software (ABI Prism, Applied Biosys-
tems) and Microsoft Excel (Redmond, WA, USA).
Statistical analysis
The one-way analysis of variance (ANOVA) and Dunnett’s 
post tests were applied using Prism 4 software (GraphPad 
Software Inc., San Diego, CA, USA). For comparison of 
bradykinin effects on erythroid progenitor cells, with or 
without TrHBMEC and HUVEC, the paired t-test was 
used with two-tail P values. The paired t-test was also used 
for comparison of bradykinin induction of NO levels with 
or without L-NAME and NG-Nitro-L-arginine.
RESULTS
Bradykinin increases NO production in  
endothelial cells
It has been previously demonstrated that bradykinin 
stimulated eNOS phosphorylation in HUVEC [9]. These 
studies were expanded to study the effect of known NO 
agonist bradykinin in endothelial cells, with a high level 
of the eNOS protein [2]. TrHBMEC were treated with dif-
ferent concentrations of bradykinin (0-20 µM) and NO 
production was measured at different time points, during 
the incubation period of 60 minutes. Bradykinin induced 
NO production in a dose- and time-dependent manner in 
TrHBMEC (Graph 1A). A more prominent elevation of NO 
levels, by bradykinin, was observed during first 15 minutes 
of treatment in cultures with TrHBMEC. After that, there 
was a sudden decrease in NO levels within 60 minutes of 
incubation. Similar and consistent dose-dependent increase 
in NO production, with an early peak after 15 minutes, 
was also obtained during the treatment of HUVEC with 20 
μМ bradykinin and L-arginine (Graph 1B). Reduced 10 μM 
dose of bradykinin also increased NO production, but with 
postponed peak after 30 minutes in HUVEC (Graph 1B). 
NO measurement was prolonged up to 6 hours of incuba-
tion and elevation of NO levels in HUVEC during bradyki-
nin treatment was not determined (not shown). Therefore, 
bradykinin stimulated NO production was confirmed in 
presented endothelial cell culture model.
Inhibition of eNOS prevented NO induction by 
bradykinin in endothelial cells
It has been already demonstrated that bradykinin stimula-
tion of eNOS phosphorylation/activation was prevented 
by the NOS inhibitor L-NAME in HUVEC [14]. To check 
NOS dependence during bradykinin stimulation of NO 
production, TrHBMEC and HUVEC cells were pretreat-
ed with the NOS inhibitors. Increased NO production in 
endothelial cells, during incubation with bradykinin, was 
blocked by competitive inhibitors of NOS such as L-NAME 
and NG-Nitro-L-arginine. TrHBMEC, preincubated with 
L-NAME, demonstrated remarkably inhibited induction 
of NO by bradykinin (Graph 2A) during first 30 minutes. 
Similar results were obtained with HUVEC treated with 
NG-Nitro-L-arginine (Graph 2B). Thus, the NOS depend-
ence was confirmed in bradykinin stimulation of NO pro-
duction in the existing endothelial cell culture model.
Bradykinin decreases eNOS mRNA levels in 
endothelial cells
In order to test whether increase in eNOS mRNA level was 
responsible for the increase in NOS activity, eNOS mRNA 
levels were measured after 24 hours of HUVEC incubation 
with bradykinin. According to our experiments, bradykinin 
inhibited eNOS mRNA levels without a dose dependent ef-
fect in HUVEC (Graph 3A). In addition, bradykinin also 
reduced the eNOS/β-actin ratio in HUVEC after 24 hours of 
treatment (Graph 3B). Therefore, the bradykinin induction 
of eNOS activity was not controlled at transcriptional level. 
Induction of NO production in TrHBMEC and 
erythroid progenitors by bradykinin
It has been shown that bradykinin stimulated NO produc-
tion in erythroid progenitors [8]. In the following experi-  
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Graph 1. Bradykinin stimulated NO production in endothelial cells: A) bradykinin treatment of TrHBMEC with addition of 1mM l-arginine; B) 
bradykinin treatment of HUVEC with addition of 1mM l-arginine during 60 minutes of incubation
Values represent means ± SEM (n=3).
* p<0.05 and ** p<0.01 versus untreated cells
Graph 2. Bradykinin NOS-dependently increased NO levels in endothelial cells: A) Bradykinin (10 μM) stimulation of NO production was prevented 
by NOS inhibitor L-NAME (0.5 mM) in TrHBMEC during the first 30 minutes of treatment; B) Bradykinin (10 μM) stimulation of NO production 
was prevented by NOS inhibitor NG-Nitro-l-arginine (0.5 mM) in HUVEC during the first 30 minutes of treatment.
Values represent means ± SEM (n=3).
* p<0.05 and ** p<0.01 versus untreated cells
Graph 3. Bradykinin decreased eNOS transcript in endothelial cells: A) bradykinin decreased eNOS mRNA levels in HUVEC after 24 hours of 
treatment; B) bradykinin decreased eNOS / β-actin ratio in HUVEC after 24 hours of treatment
Values represent means ± SEM (n=3).
* p<0.05 and ** p<0.01 versus untreated cells
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ments, the induction of extracellular and intracellular pro-
duction of NO by bradykinin was observed in TrHBMEC 
and erythroid progenitors during co-culture studies. First, 
a dose-dependent increase in extracellular NO levels was 
demonstrated in TrHBMEC during stimulation by brady-
kinin as measured by fluorescent probe DAF-2 (Graph 4A). 
Intracellular NO levels, determined by the cell-permeable 
DAF-2DA probe, were low and did not change significant-
ly during bradykinin stimulation (Graph 4A). To examine 
intracellular NO presence in both erythroid progenitors 
and TrHBMEC during co-culture studies and bradykinin 
stimulation, flow cytometry was used to label simultane-
ously the erythroid progenitors by CD34+ and TrHBMEC 
by CD31+ antibody as well as with the fluorescent probe 
DAF-2DA (Graph 4B). The labeled TrHBMEC were highly 
enriched with intracellular NO (about 80%) and the same 
applied for erythroid progenitors during stimulation by 
bradykinin in co-cultures (Graph 4B).
Gamma-globin gene expression of stimulated 
erythroid progenitors in co-culture with 
endothelial cells 
As already demonstrated, hydroxycarbamide significantly 
increased γ-globin mRNA expression in erythroid progen-
itors of co-culture experiments with TrHBMEC and that 
increase was higher in comparison with hydroxycarbamide 
effect on erythroid progenitors only [12]. To examine the 
general ability of endothelial cell-derived NO to affect 
γ-globin gene expression, the erythroid progenitors were 
stimulated by bradykinin. Low- and short-term induced 
NO production (up to 0.08 µM within first 15-30 min-
utes) by bradykinin (Graphs 1 and 2) failed to increase 
γ-globin mRNA expression in erythroid progenitor cells 
only (Graph 5A), as well as in co-culture of erythroid pro-
genitors with TrHBMEC (Graph 5B) or HUVEC (Graph 
6A) after 24 hours of treatment. It has been also shown that 
Graph 5. Bradykinin induction of γ-globin gene expression in erythroid progenitors: A) Gamma-globin gene expression in erythroid progenitors 
during treatment with bradykinin on day 5/6 of culture; B) Gamma-globin gene expression in co-cultures of TrHBMEC and erythroid progenitors 
during treatment with bradykinin on day 5/6 of culture
Values represent means ± SEM (n=3).
Graph 4. Stimulation of NO production in TrHBMEC and erythroid progenitors by bradykinin: A) Detection of extracellular and intracellular NO 
levels in TrHBMEC with fluorescent indicators DAF-2 and DAF-2DA (per 10 μM, 1x104 cells) during bradykinin treatment, respectively; B) Flow 
cytometry of hematopoietic progenitor cells (2x105, on day 6) by CD34+ antibody and TrHBMEC (1x105) by CD31+ antibody, plus DAF-2DA (10 μM), 
in co-culture system treated with 1 mM L-arginine and 10 μM bradykinin.
Values represent means ± SEM (n=3).
** p<0.01 compared to untreated cells  
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bradykinin failed to increase γ/ß ratio in erythroid progen-
itor cells co-cultured with HUVEC after 24 hours (Graph 
6B). Therefore, the endothelial cell-derived NO, induced 
by bradykinin, was not sufficient to increase γ-globin gene 
expression in erythroid progenitor cells.
DISCUSSION
It has been demonstrated that bradykinin dose- and time-
dependently increased NO production in TrHBMEC and 
HUVEC. Generally, the effects of bradykinin were similar 
in both types of endothelial cells. Moreover, NO produc-
tion in endothelial cells was prevented by NOS inhibi-
tors. Bradykinin did not appear to increase eNOS protein 
levels by increasing eNOS transcription. After 24 hour-
treatment of HUVEC, bradykinin inhibited eNOS mRNA 
levels. Concomitant increase of NO levels was observed in 
TrHBMEC co-cultured with erythroid progenitors. Brady-
kinin failed to increase γ-globin expression in erythroid 
progenitor cells only as well as in co-cultures of erythroid 
and TrHBMEC or HUVEC cells. In addition, bradykinin 
did not increase γ/β ratio in co-culture of erythroid pro-
genitors and HUVEC. According to these results, the NO 
production induced by physiological stimulator bradyki-
nin was not sufficient for enhancement of γ-globin gene 
expression.
It has been reported that cGMP-dependent signaling 
may be important for erythroid HbF induction. High 
gene expression of cGMP-specific phosphodiesterase 9A 
(PDE9A) was found in CD34+-derived erythroid cells and 
K562 erythroleukemic cells, indicating a high hematopoi-
etic cell expression [15]. Inhibition of PDE9A enzyme sig-
nificantly increased production of the γ-globin gene in 
K562 cells [15]. In addition, inhibition of PDE9 amplified 
the cGMP-elevating effects of hydroxycarbamide [16]. 
According to early studies, γ-globin mRNA levels were 
unaffected by NO production of K562 erythroleukemic 
cells retrovirally transduced with inducible NOS (iNOS), 
while γ-globin protein expression was reduced in the NO-
producing cells in relation to the amount of produced NO 
[17]. NO did not directly inhibit hemoglobin synthesis, but 
likely acted gradually in heme synthesis [18]. Recently, it 
has been shown that increased expression of HbF was ac-
companied by increased levels of NO metabolites (NOx) 
and bioavailability [7]. Sickle cell anemia patients with 
high levels of HbF showed the concomitant elevation of 
serum levels of NOx [19]. The direct stimulation of cellular 
NO and cGMP signaling in erythroid progenitors acted 
as possible mechanism of γ-globin gene activation [20]. 
It has been reported that NOS substrate arginine dose-
dependently increased BFU-E colonies without affecting 
HbF synthesis. However, the combination of arginine and 
hydroxycarbamide increased HbF synthesis when com-
pared with hydroxycarbamide treatment only. This syner-
gistic effect on HbF synthesis in human erythroid progeni-
tors was NO dependent [21]. According to our results, the 
NO inducer bradykinin did not stimulate γ-globin gene 
expression in erythroid progenitors. Therefore, both NOS 
substrate arginine and physiologic stimulator bradykinin 
were not sufficient for enhancement of γ-globin gene ex-
pression in two independent studies.
The bradykinin receptor type 2 (B2R) was expressed 
constitutively in endothelial cells, while B1R was upregu-
lated by inflammatory mediators. B2R-mediated eNOS 
activation led to lower and transient (about 5 min.) out-
put of NO in endothelial cells whereas in cytokine-treated 
endothelial cells, B1R activation led to very high and pro-
longed (about 90 min.) NO production that was mediated 
by post-translational activation of iNOS [22]. According 
to our previous reports, bradykinin-induced NO produc-
tion lasted 15-30 min. in endothelial cells, while butyric 
acid and hydroxycarbamide stimulated a protracted NO 
production, enduring couple of hours to couple of days 
[9, 13]. B2R coupling to Gαq/11 or Gαi/o resulted in 
downstream activation of PLC, leading to the formation 
of diacylglycerol and inositol 1,4,5-trisphosphate (IP3), 
which increased cytoplasmic Ca2+ concentrations involved 
in the generation of NO. It has been already proposed that 
γ-globin stimulation was regulated via G proteins of the 
Gαs (stimulation of cAMP/PKA) and Gαq (stimulation 
of intracellular Ca2+) families [23]. Therefore, bradykinin 
Graph 6. Bradykinin induction of γ-globin gene expression in co-cultures of erythroid progenitors and endothelial cells: A) Gamma-globin gene 
expression in co-cultures of HUVEC and erythroid progenitors during treatment with bradykinin on day 5/6 of culture; B) Gamma/beta-globin 
ratio in co-cultures of HUVEC and erythroid progenitors during 24 hours of treatment with bradykinin on day 6 of culture
Values represent means ± SEM (n=3).
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just partially activated Gαq and, furthermore stimulated a 
reverse Gαi (inhibited cAMP/PKA pathway). Bradykinin 
induced biphasic rise in intracellular Ca2+, an initial tran-
sient peak generated from the intracellular stores, followed 
by the sustained plateau phase caused by extracellular Ca2+ 
entry through calcium channels in the plasma membrane 
[24]. In our previous report, hydroxycarbamide increased 
intracellular Ca2+ after 2-6 minutes and generally had a 
protracted effect in endothelial cells [9]. Stimulation of 
eNOS phosphorylation at Ser1177 and dephosphorylation 
at Thr495 also resulted from B2R stimulation [25]. A tran-
sient, about 5 min., eNOS phosphorylation at Ser1177 by 
bradykinin, as well as by hydroxycarbamide, has been al-
ready observed [9]. This comparative review demonstrated 
that bradykinin just partially fulfilled activities of standard 
γ-globin inducers, such as hydroxycarbamide.
Hydroxycarbamide increased HbF levels through the 
NO-dependent activation of soluble guanylyl cyclase in 
erythroid cells, while NO increased γ-globin levels, γ/β-
globin ratio and HbF levels in human erythroid cells [11]. 
Co-culture of human bone marrow endothelial cells and 
erythroid progenitor cells also induced γ-globin mRNA 
expression in the presence of hydroxycarbamide. The 
persistent and modest NO production (between 0.6 and 
1.3 μM), by stimulated hematopoietic stromal cells, pref-
erably increased γ-globin gene expression. The erythroid 
progenitor cells co-cultured either with macrophages or 
endothelial cells stimulated by iNOS inducers and hydrox-
ycarbamide, respectively, led to elevated levels of γ-globin 
gene expression as compared to the erythroid cells only 
[12]. This supplemented NO production, in the hemat-
opoietic microenvironment, has the potential to increase 
HbF synthesis in erythroid progenitors with low hemo-
globin quantity and apparently low NO scavenging activity.
CONCLUSION
According to presented results, bradykinin did not change 
significantly γ-globin gene expression in solitary eryth-
roid progenitors and in co-cultures with endothelial cells. 
These findings demonstrated that determined physiologic 
stimulation of the constitutive NO production was not suf-
ficient for γ-globin gene induction. Further studies should 
explore the activity of individual G proteins related to G 
protein coupled receptors during stimulation of γ-globin 
expression, because eNOS was regulated by reversible and 
inhibitory interactions with G-protein-coupled receptors 
in endothelial cells [26]. Using this approach, the upward 
part of NO/cAMP and NO/cGMP signaling pathways will 
be described with the accent to explore their activities be-
tween membrane receptors and nucleus. This report will 
support potential studies of hematopoietic microenviron-
ment to explore a therapy for hemoglobinopathies cur-
rently treated with hydroxycarbamide.
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КРАТАК САДРЖАЈ
Увод Хи  дрок  си  кар  ба  мид, ко  ји се ко  ри  сти у ле  че  њу хе  мо  гло-
би  но  па  ти  ја, под  сти  че ства  ра  ње азот-мо  нок  си  да (NО) ка  ко 
у при  мар  ним људ  ским ен  до  тел  ним ће  ли  ја  ма пуп  ча  не ве  не 
(HU VEC), та  ко и у из  ме  ње  ној ен  до  тел  ној ће  лиј  ској ли  ни  ји по-
ре  клом из ко  шта  не ср  жи (TrHB MEC). Шта  ви  ше, NО по  ве  ћа-
ва ства  ра  ње γ-гло  би  на и фе  тал  ног хе  мо  гло  би  на у људ  ским 
про  ге  ни  то  ри  ма ери  тро  по  е  зе.
Циљ ра  да Да би  смо уста  но  ви  ли да ли јед  но  став  на фи  зи  о-
ло  шка сти  му  ла  ци  ја ства  ра  ња NО од ком  по  нен  ти ми  кро  сре-
ди  не хе  ма  то  по  е  зе мо  же по  ве  ћа  ти екс  пре  си  ју γ-гло  бин  ског 
ге  на, ис  пи  ти  ва  ли смо ефек  те бра  ди  ки  ни  на, већ по  зна  тог 
сти  му  ла  то  ра ства  ра  ња NО.
Ме  то  де ра  да Сту  ди  ја је из  ве  де  на у за  јед  нич  ким кул  ту  ра  ма 
људ  ских про  ге  ни  то  ра ери  тро  по  е  зе са TrHB MEC или HU VEC 
и ис  пи  ти  ва  на хе  ми  лу  ми  ни  сцент  ним ме  ре  њем NО по  сред-
ством озо  на, као и при  ме  ном кван  ти  та  тив  ног RT-PCR на 
ген  ском ни  воу.
Ре  зул  та  ти У скла  ду с прет  ход  ним из  ве  шта  ји  ма, по  ка  за  ли 
смо да ен  до  ге  ни фак  тор бра  ди  ки  нин по  ве  ћа  ва ства  ра  ње 
NО у ен  до  тел  ним ће  ли  ја  ма на до  зно и вре  мен  ски за  ви  сан 
на  чин (0,1–0,6 μM до 30 ми  ну  та). Ово ства  ра  ње NО у HU VEC 
и TrHB MEC иза  зва  но бра  ди  ки  ни  ном бло  ки  ра  но је од стра  не 
кон  ку  рент  ских ин  хи  би  то  ра NО-син  та  зе (NОЅ), по  ка  зу  ју  ћи 
NОЅ-за  ви  сност. Утвр  ди  ли смо да бра  ди  ки  нин зна  чај  но сма-
њу  је ства  ра  ње иРНК ен  до  тел  не фор  ме NОЅ (еNОЅ), као и од-
нос еNОЅ и β-ак  ти  на у HU VEC (дво  стру  ко ма  ње). По  ред то  га, 
бра  ди  ки  нин не по  ве  ћа  ва екс  пре  си  ју иРНК γ-гло  бин  ског ге  на 
ни у за  себ  ним про  ге  ни  то  ри  ма ери  тро  по  е  зе, ни  ти у за  јед-
нич  ким кул  ту  ра  ма про  ге  ни  то  ра ери  тро  по  е  зе са TrHB MEC 
или HU VEC по  сле 24 са  та трет  ма  на. Бра  ди  ки  нин не ме  ња ни 
од  нос γ и β гло  би  на у за  јед  нич  ким кул  ту  ра  ма про  ге  ни  то  ра 
ери  тро  по  е  зе са HU VEC.
За  кљу  чак Ак  ти  ва  ци  ја еNОЅ иза  зва  на бра  ди  ки  ни  ном до  во  ди 
до крат  ког и ма  лог по  ве  ћа  ња NО у ен  до  тел  ним ће  ли  ја  ма, 
што је не  до  вољ  но да под  стак  не екс  пре  си  ју ге  на за γ-гло  бин. 
Ови ре  зул  та  ти на  гла  ша  ва  ју ва  жност по  ве  ћа  ног и про  ду  же-
ног ства  ра  ња NО ра  ди сти  му  ла  ци  је екс  пре  си  је γ-гло  би  на.
Кључ  не ре  чи: бра  ди  ки  нин; ен  до  тел  не ће  ли  је; про  ге  ни  то  ри   
ери  тро  по  е  зе; азот-мо  нок  сид; га  ма-гло  бин
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